Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study

• DOI: 10.1016/j.cgh.2025.01.012
• Publication Date: 2025-03-08T21:23:28Z
• Authors: Jalpa Devi; Anthony Xu; Molly Stone; Anish Patel; Abdul Khan; Nikhil Reddy; Jeremy Klein; Navreet Chowla; Caroline Benson; Bryan Christopher...; Katherine Huang; Fnu Jaiprada; Marc Fenster; Ryan Ungaro; Joel Pekow; Amanda M. Johnson; Andres J. Yarur; Richa Shukla; Julia Huecker; Shrinivas Bishu; Martin Gregory; David Dulaney; David T. Rubin; Parakkal Deepak
• Keywords: Crohn disease

We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor (JAKi) in patients with Crohn's disease (CD). A retrospective analysis was conducted across nine centers United States, focusing on adults CD treated UPA 45 mg as induction therapy for active luminal disease. The co-primary endpoints were clinical remission at 12 weeks (Harvey Bradshaw Index ≤ 4 or absence symptoms physician's global assessment) endoscopic 6 months (SEMA-CD score 0-1 ulcers). Secondary outcomes included clinical, radiographic histologic outcomes, adverse events (AEs). study 334 (median age 34 years duration years, 44.6% female). Clinical achieved 52.1% 55.9% months. Endoscopic observed 42.7% patients. Advanced (AT)-naive a higher proportion (58.6%) (97.7%) compared one prior AT (53.3% 66.7%) two more exposures (50.2% 40.5%), respectively. BMI longer associated lower odds weeks. AEs reported 13.5% discontinued 19.1%. effective inducing group CD, even exposure multiple advanced therapies. No new concerns identified.